Areas with Risk of Dengue: CDC map, criteria, and global reach

Areas with Risk of Dengue: CDC Map, Criteria, and Global Reach

CDC says nearly half the world's population lives in areas with dengue risk, spanning the Americas, Africa, the Middle East, Asia, and the Pacific Islands. This update explains the CDC risk classifications and the altitude factor that helps define exposure areas.

IntelligenceRegulatory Impact▾

CDC decisions frame this story. Regulatory relevance is medium for Dengue, with Dengue Vaccine most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Approximately 4 billion people—nearly half the world's population—live in dengue-risk areas according to the CDC.
• The CDC uses a two-tier case-history framework to classify risk: frequent/continuous (more than 10 locally acquired cases in at least 3 of the previous 10 years) and sporadic/uncertain (at least 1 locally acquired case in the last 10 years).
• Mosquitoes capable of spreading dengue typically live below 6,500 feet in elevation, a practical threshold for assessing geographic exposure.
• Dengue transmission is documented across the Americas, Africa, the Middle East, Asia, and the Pacific Islands, making it a truly global public health concern.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. the parties involved reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

How the CDC Defines Dengue Risk Areas

The CDC's Areas with Risk of Dengue page provides the current global framework for dengue exposure mapping. The agency employs a transparent, case-based classification system that separates regions into two categories.

Frequent or continuous risk areas show evidence of more than 10 locally acquired dengue cases in at least 3 of the previous 10 years. This threshold identifies regions where dengue transmission is established and recurrent. Sporadic or uncertain risk areas have documented at least 1 locally acquired case during the last 10 years, indicating potential for transmission even if cases are infrequent.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for Dengue. Expect implications for pricing, access, and launch sequencing.

Geographic Scope and the Altitude Factor

Dengue is a common disease affecting the Americas, Africa, the Middle East, Asia, and the Pacific Islands. The geographic footprint is vast, encompassing both endemic regions and popular travel destinations in the Caribbean, Central America, South America, and Southeast Asia.

A key practical element in dengue risk assessment is elevation. Mosquitoes capable of spreading dengue usually live in places below 6,500 feet. This altitude threshold provides a useful tool for clinicians, travelers, and public health officials to narrow exposure risk within regions classified as dengue-endemic.

IntelligenceStrategic Takeaways▾

Approximately 4 billion people—nearly half the world's population—live in dengue-risk areas according to the CDC. The CDC uses a two-tier case-history framework to classify risk: frequent/continuous (more than 10 locally acquired cases in at least 3 of the previous 10 years) and sporadic/uncertain (at least 1 locally acquired case in the last 10 years) . Mosquitoes capable of spreading dengue typically live below 6,5

Population at Risk and Vaccine Development Context

Approximately 4 billion people live in areas with a risk of dengue, representing a substantial target population for prevention strategies. Several dengue vaccine candidates are currently in clinical development.

Takeda has completed a Phase 3 study of a dengue vaccine in healthy children, teenagers, and adults in India. The company is also recruiting for a Phase 3 trial of dengue tetravalent vaccine (TDV) in adults aged 45 to 60 and over 60 to 79 years, as well as recruiting for a study in children and teenagers to evaluate whether TDV vaccination lowers the chance of hospital stays for dengue. Merck Sharp & Dohme is recruiting for a Phase 3 trial of V181 dengue vaccine in healthy participants 2 to 17 years of age.

Frequently Asked Questions